Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold  by Chaturvedi, Nish et al.
Kidney International, Vol. 60 (2001), pp. 219–227
CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS
Microalbuminuria in type 1 diabetes: Rates, risk factors and
glycemic threshold
NISH CHATURVEDI, SIMONA BANDINELLI, RUGGERO MANGILI, GUISEPPE PENNO,
RAOUL E. ROTTIERS, and JOHN H. FULLER, on behalf of the EURODIAB
PROSPECTIVE COMPLICATIONS STUDY GROUP1
EURODIAB, University College London, London, England, United Kingdom; Department of Endocrinology and Metabolism,
University of Pisa and Azienda Ospedaliera Pisana, Pisa, and Ospedale San Raffaele, Milano, Italy; and Diabetes Department,
University Hospital of Gent, Gent, Belgium
Microalbuminuria in type 1 diabetes: Rates, risk factors and The occurrence of microalbuminuria in a patient with
glycemic threshold. type 1 diabetes is clearly indicative of an enhanced risk
Background. The occurrence of microalbuminuria in type 1 of nephropathy and cardiovascular disease [1–4]. Thediabetes is strongly predictive of renal and cardiovascular dis-
identification of such individuals is an important chal-ease and is still likely to occur despite improvements in glycemic
lenge to care providers. While microalbuminuria cancontrol. A better understanding of microalbuminuria is required
to inform new interventions. We determined the incidence and be substantially delayed by tight glycemic control [5],
risk factors for microalbuminuria [albumin excretion rate (AER) achieving the degree of control encouraged by the results
20 to 200 g/min] in the EURODIAB Prospective Complica-
of the Diabetes Control and Complications Trial (DCCT)tions Study.
remains impractical for many centers. Additionally, thereMethods. This is a seven-year follow-up (between 1988 and
1991) of 1134 normoalbuminuric men and women (aged 15 to are claims that there is a glycemic threshold below which
60) with type 1 diabetes from 31 European centers. Risk factors the risk of progression to microalbuminuria remains static
and AER were measured centrally. [6], and although not confirmed by other reports [7, 8],Results. The incidence of microalbuminuria was 12.6% over
such claims have important implications for care guide-7.3 years. Independent baseline risk factors were HbA1c (7.1
lines. It is still likely that progression to microalbumin-vs. 6.2%, P 0.0001) and AER (9.6 vs. 7.8 g/min, P 0.0001)
and, independent of these, fasting triglyceride (0.99 vs. 0.88 uria will occur in a substantial proportion of patients,
mmol/L, P  0.01), low-density lipoprotein cholesterol (3.5 vs. and therefore there is a need to obtain valid estimates
3.2 mmol/L, P  0.02), body mass index (24.0 vs. 23.4 kg/m2,
of progression and to explore the role of risk factorsP  0.01), and waist to hip ratio (WHR; 0.85 vs. 0.83, P 
other than glycemic control and diabetes duration that0.009). Triglyceride and WHR risk factors were nearly as strong
as AER in predicting microalbuminuria (standardized regres- may provide further clues for novel interventions.
sion effects of 1.3 for triglyceride and WHR and 1.5 for AER). The EURODIAB Prospective Complications Study
Blood pressure at follow-up, but not at baseline, was also raised (PCS) is ideally placed to address some of these questions.in those who progressed. There was no evidence of a threshold
To our knowledge this is the largest cohort study ofof HbA1c on microalbuminuria risk.
people with type 1 diabetes, with standardized measuresConclusions. The incidence of microalbuminuria in patients
with type 1 diabetes remains high, and there is no apparent of albumin excretion rate (AER) at both baseline and
glycemic threshold for it. Markers of insulin resistance, such follow-up. We determined the incidence of microalbu-
as triglyceride and WHR, are strong risk factors. Systemic blood
minuria, examined risk factors, and determined whetherpressure is not raised prior to the onset of microalbuminuria.
there was evidence for a glycemic threshold.
METHODS
1 A complete list of members is in the Appendix. A total of 3250 men and women with type 1 diabetes
were recruited from 31 centers in 16 European countries,Key words: blood sugar control, renal disease, cardiovascular disease,
albuminuria, insulin resistance. and were aged between 15 and 60 at the baseline investi-
gation phase (1989 to 1991) [9]. The diagnosis of type 1
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Re-examination occurred on average of between six and pared using linear regression by center. At worst, local
measurements for an individual center were performedeight years after baseline investigations.
At follow-up, the patient’s complication status was on 58% (35 out of 60) of all samples received centrally
in London; this still was sufficient to estimate a slopeagain measured using the same protocol as baseline [9].
Two blood pressure measurements were taken at both between central and local HbA1c. For each center, the
mean of the previous two years of data on HbA1c forvisits, using the same standard random zero sphygmoma-
nometer, and their mean value was used in all analyses. each individual was calculated. The regression equation
then was used to convert this local mean to a central, thatThe previous two years (8 visits) of values of locally
measured HbA1c were recorded. Two 24-hour urine col- is, London mean. If a center had changed lab methods for
HbA1c, only those measurements using methods that welections were performed (only one was performed at
baseline). Patients performed collections on two consec- had been able to standardize were used in these analyses.
For the assessment of a threshold effect and for compari-utive days to minimize variability. Samples were tested
for infection by dipstick (Nephur test), and if positive, sons between baseline and follow-up HbA1c, a conversion
factor to the DCCT measure was calculated. This againthe collections were discarded and a fresh collection was
advised after any infection had been treated. If the dip- was derived from a linear regression plot of measures
of HbA1c comparing results from the London laboratorystick was negative, aliquots were frozen and sent to Lon-
don for analysis of urinary albumin, using an immunotur- at baseline against those using the DCCT method. This
was DCCT HbA1c  1.0289  London HbA1c  1.5263.bidimetric method [10] that included goat anti-human
albumin antisera (Sanofi Diagnostics Pasteur Inc., MN, A similar technique was employed at follow-up so that
direct comparisons between HbA1c at baseline and HbA1cUSA) and human serum albumin standards (ORHA
20/21 grade HSA; Behring Diagnostics, Hoechst UK Ltd., could be made. This formula was: DCCT HbA1c 
0.9633  London HbA1c  0.0709.Hounslow, Middlesex, UK). The same laboratory was
used for both baseline and follow-up studies. The coeffi- Baseline and follow-up characteristics for incidence
were calculated using regression techniques for continu-cient of variation for the follow-up specimens was 34%,
reflecting the known variability in this measure. Blood ous variables and proportions for categorical variables.
An adjustment was then made for those variables thatsamples were taken, with the patient fasting if possible,
for measurement of lipids. At both baseline and follow- were statistically significantly related to risk of microalbu-
minuria for HbA1c and diabetes duration, which a prioriup, these samples were sent to a central lab, and the
methods used at baseline were standard enzymatic meth- were thought to be the main risk factors for progression.
A breakpoint or threshold effect for the relationshipods (Boehringer Mannheim, East Sussex, UK) on a co-
bas-bio centrifugal analyzer (Roche, Welwyn Garden between HbA1c and microalbuminuria was tested for
using a two-phase segmented-weighted regression analy-City, Herts, UK) [11–13]. Low-density lipoprotein (LDL)
cholesterol was calculated according to the Friedewald sis, which fits two straight lines through a series of defined
points [17]. These points were calculated by logistic re-formula [14]. Glycosylated hemoglobin (HbA1c) was
measured with an enzyme immunoassay using a mono- gression adjusted for diabetes duration. This segmented
regression was compared with the line of best fit, usingclonal antibody against HbA1c (Dako, Ely, UK) [15]. The
reference range for this assay is 2.9 to 4.8%. A sample weighted linear regression. Logistic regression was used
to test for a threshold effect [18].was sent locally for measurement of HbA1c. At baseline,
the coagulation factors fibrinogen and von Willebrand Multivariate regression models are often used to un-
derstand the relative importance of several predictivefactor (vWF) were also measured [16].
variables for a given outcome. However, the direct com-
Statistical analysis parison of the size of the  coefficients of these explana-
tory variables is problematic, as, for example, a one-yearThese analyses are restricted to those patients who
were normoalbuminuric (AER20 g/min) at baseline. increase in age cannot be said to be equivalent to a
1% increase in HbA1c. Standardized regression effectsMicroalbuminuria was defined as an AER of between
20 and 200 g/min, based on the arithmetic mean of the (SREs) were used to overcome this limitation. SREs
were calculated for continuous variables by multiplyingtwo follow-up urine collections. Two urine collections
were available on 91% of patients; the value of the soli- the  estimate from logistic regression models by the
standard deviation of that variable; in this case, all log-tary specimen was used in the remainder. Centrally mea-
sured HbA1c was used in most analyses, but to get a transformed variables were not converted back. This
allowed the direct comparison of the degree of impor-measure of previous glycemic control, which was as-
sessed locally, the following approach was used to stan- tance of each variable by standardizing for population
variance. Multivariate models were restricted to thosedardize local clinic measures to the central measure. The
central measurement and local measurement performed individuals who had complete data on all included risk
factors (N  715). Much of the missing data was due toon aliquots of the same sample at follow-up were com-
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Fig. 1. Patient flow chart.
Table 1. Comparison of baseline data for those with and without There were no significant differences in risk factors at
an albumin excretion rate (AER) measurement at follow-up
baseline, apart from HbA1c, which was 6.7% in those
Availability of AER measurement with no follow-up data and 6.3% in those with follow-
at follow-up up data (P  0.0001), and fasting triglyceride (0.96 vs.
No (N  691) Yes (N  1134) P value 0.89 mmol/L, P  0.004).
Age years 3210 3210 0.1 The incidence of microalbuminuria was 12.6% (143/
Duration years 139 149 0.7 1134, 95% CI, 10.7 to 14.7%), a rate of 1.8 per 100
HbA1c % 6.71.8 6.31.7 0.0001 person-years. This did not differ by sex, being 13.2% (73AERa lg/min 7.7 (5.2, 11.6) 7.9 (5.6, 11.8) 0.3
Systolic BP mm Hg 11816.8 11814.9 0.3 out of 554) in men and 12.1% (70 out of 580) in women
Diastolic BP mm Hg 7410.4 73.410.7 0.5 (P  0.5), equivalent to rates of 1.9 and 1.7 per 100
Cholesterol mmol/L 5.21.1 5.21.0 0.1
person-years, respectively. The risk of progression toTriglyceridea mmol/L 0.96 (0.75, 1.21) 0.89 (0.65, 1.12) 0.004
WHR 0.840.11 0.830.10 0.6 macroalbuminuria (an AER200 g/min) was 1.7% (19
Data are mean  SD. Abbreviations are: BP, blood pressure; WHR, waist out of 1134, 95% CI, 1.0 to 2.6%). Risk factors in these
to hip ratio. 19 patients were similar to those for progressors to micro-a Geometric mean (25th, 75th centiles)
albuminuria, however, with such small numbers it would
be wrong to attach too much significance to these find-
ings. On the other hand, it may be misleading to simply
the lack of a fasting triglyceride measurement at baseline combine these patients with the group progressing to
(760 out of 1115 fasting samples available), but this ratio microalbuminuria. These 19 patients therefore were ex-
did not differ by progressor status. Other risk factors cluded from subsequent analyses.
were compared in those who did and did not have a Risk factors at baseline for progression to microalbu-
fasting triglyceride measurement, and the risk factor re- minuria did not include diabetes duration, but did include
lationships were found to be identical. HbA1c and AER (Table 2). A model fitting a breakpoint
to the association between HbA1c and risk of micro-
RESULTS albuminuria was not superior to a log linear model (Fig.
2). Other univariate associations with progression toThe mean follow-up was 7.3 years. Out of the 3250
microalbuminuria were noted for cholesterol, fasting tri-patients examined at baseline, 1865 were normoalbumi-
glyceride, high-density lipoprotein (HDL) cholesterol,nuric and available for follow-up examination. Of these,
low-density lipoprotein (LDL) cholesterol, body mass in-data on AER at follow-up were available on 1134 pa-
dex (BMI), and waist to hip ratio (WHR). In a sex-specifictients (Fig. 1). Follow-up rates by center varied from
analysis for the latter, WHR was greater at baseline in44 to 94%, but bore no association with incidence of
those who progressed to microalbuminuria comparedmicroalbuminuria. Baseline data were compared in those
with those who did not for both men (0.89 vs. 0.87, P who were potentially available for follow-up, but on
0.07) and women (0.82 vs. 0.79, P  0.06). The presencewhom there were no follow-up AER data (that is, 550
of peripheral neuropathy and retinopathy was also6  135, excluding those who had died) with those who
did provide a urine collection at follow-up (Table 1). strongly predictive of progression to microalbuminuria.
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Table 2. Risk factors at baseline by progression to microalbuminuria at follow-up
Progression to microalbuminuria
Yes (N  143) No (N  972) P value
Age years 3310 3210 0.8
Duration years 1410 139 0.3
Systolic BPb mm Hg 11618 11715 0.8
Diastolic BPb mm Hg 7310 7311 0.7
HbA1c % 7.11.8 6.21.7 0.0001
Cholesterol mmol/L 5.31.0 5.11.0 0.04
Fasting triglyceridea mmol/L 1.05 (0.75, 1.50) 0.87 (0.64, 1.08) 0.0005
HDL mmol/L 1.440.42 1.530.41 0.02
LDL mmol/L 3.60.9 3.20.9 0.002
vWFa U/ml 1.08 (0.85, 1.40) 1.07 (0.87, 1.39) 0.8
Fibrinogen g/l 3.250.85 3.120.81 0.2
Height cm 16911 1699 0.8
Weight kg 6912 6711 0.09
BMI kg/m2 24.12.7 23.42.8 0.006
WHR 0.860.11 0.830.09 0.003
Insulin/kg body weight U/kg 0.64 (0.54, 0.81) 0.64 (0.53, 0.79) 0.8
AERa lg/min 9.57 (6.77, 13.85) 7.69 (5.45, 11.31) 0.0001
Peripheral neuropathy % 27 17 0.004
Autonomic neuropathy % 33 32 0.8
Any retinopathy % 49 35 0.005
Current smoker % 31 27 0.4
Inject insulin 	2/day % 41 51 0.03
Cardiovascular disease % 8 7 0.7
Data are mean  SD. Abbreviations are: BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; vWF, von Willebrand factor; BMI,
body mass index; WHR, waist to hip ratio; AER, albumin excretion rate.
a Geometric mean (25th, 75th centiles)
b Mean, excluding those on antihypertensive therapy
Even in the univariate analysis, baseline blood pres- Markers of endothelial function such as vWF and pres-
ence of cardiovascular disease at baseline were not asso-sure was not associated with progression, whether it was
calculated as a mean for the whole population (systolic ciated with progression of renal disease.
Once duration, HbA1c, and baseline AER were ac-118 mm Hg and diastolic 73 mm Hg in both groups), the
mean for all those not on antihypertensive therapy (as counted for, the risk factors that remained significantly
related to risk of progression to microalbuminuria wereshown in Table 2), or as a median, with all treated hyper-
tensives assigned to the upper decile of the blood pres- fasting triglyceride, HDL cholesterol, LDL cholesterol,
BMI, and WHR (Table 3). The presence of any retinopa-sure distribution (systolic 114 mm Hg in progressors, 117
in nonprogressors, P  0.3, diastolic 73 mm Hg in both thy at baseline increased the risk of progression to micro-
albuminuria 1.8-fold (95% CI, 1.1 to 2.8, P  0.02).progressors and nonprogressors, P  0.5) [19]. At base-
line, 5% (N 58) of these patients were on antihyperten- Standardized regression estimates were calculated, en-
tering those significant risk factors that appeared to besive therapy. This proportion did not differ between
those who went on to progress to microalbuminuria com- independent of baseline AER and HbA1c simultaneously
into a model, but not including the presence of otherpared with those who remained normoalbuminuric (5
vs. 6%, respectively, P  0.9). At follow-up, 12.6% of complications (Table 4). The factors that remained statis-
tically significant in this multivariate model were HbA1c,persistently normoalbuminuric and 18% of microalbumi-
nuric patients were on antihypertensive therapy. Of the AER, fasting triglyceride, and WHR. When LDL was
added to this model, the SRE was 1.24 (95% CI, 0.95 to122 normoalbuminuric patients on antihypertensive ther-
apy, 88 (72%) were on angiotensin-converting enzyme 1.62, P  0.1), and the effect for triglyceride was attenu-
ated to 1.26 (95% CI, 1.01 to 1.56, P  0.08).inhibitors, and 29 (24%) on calcium channel blockers.
The rest of the subjects were on other medications. Indi- Univariate standardized regression effects for triglyc-
erides were 1.52 (95% CI, 1.23 to 1.87, P  0.001) andcations for treatment of these patients were a history
of hypertension at baseline (N  61) or follow-up (an for WHR 1.32 (95% CI, 1.08 to 1.61, P  0.008). Both
of these associations were attenuated but not abolishedadditional 34). Of the remaining patients with no history
of hypertension, two were prescribed therapy because of in the multivariate model. Use of lipid-lowering therapy
was confined to 2.7% of nonprogressors (26 out of 972)persistent microalbuminuria. Thus, we could find reasons
for therapy in 80% of patients on antihypertensive medi- and 4.9% (7 out of 143) of progressors. Their exclusion
did not alter the results shown here.cation.
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Fig. 2. Relationship between glycemic control at baseline and risk of microalbuminuria at follow-up; testing for a threshold effect (numbers of
patients progressing to microalbuminuria/total at risk). Symbols are: () Odds ratio estimated with logistic regression, adjusted for baseline
duration; () line of best fit, using weighted linear regression; () segment 1 of the threshold model (at 8.5% London HbA1c); () segment 2 of
the threshold model.
Table 3. Baseline risk factors for progression to microalbuminuria after adjusting for duration, HbA1c and AER
Progression to microalbuminuria
Yes No
(mean) (mean) P value
Fasting triglyceridea mmol/L 0.99 (0.91, 1.09) 0.88 (0.85, 0.90) 0.01
HDL cholesterol mmol/LSE 1.440.03 1.530.01 0.02
LDL cholesterol mmol/LSE 3.50.10 3.20.03 0.02
BMI kg/m2SE 24.00.2 23.40.1 0.01
WHPSE 0.850.008 0.830.003 0.009
Relative risk of progressions to microalbuminuria
Any retinopathy (95% CI) 1.8 (1.1, 2.8) 1.0 0.02
Abbreviations are in Table 2.
a Geometric mean (25th, 75th centiles)
When risk factors at follow-up between those who These results did not change qualitatively when those
on antihypertensive therapy at either baseline or follow-became microalbuminuric and those who remained nor-
moalbuminuric were compared, a different risk profile up were removed or when the median blood pressure
was used. Furthermore, follow-up HbA1c, the previousassociated with microalbuminuria emerged. Thus, both
systolic and diastolic blood pressure values at follow- two years worth of HbA1c, and fasting triglyceride were
higher at follow-up in progressors compared with non-up were higher in the incident cases than in those who
remained normoalbuminuric, even when baseline AER progressors. Change in risk factor status over the follow-
up period was also calculated. Thus, while systolic bloodwas taken into account (systolic 123 vs. 118 mm Hg, P
0.0005, diastolic 75 vs. 73 mm Hg, P  0.02; Table 5). pressure increased by 5.8  17.6 (SD) mm Hg in prog-
Chaturvedi et al: Risk of microalbuminuria in type 1 diabetes224
Table 5. Risk factors at follow-up by progression toTable 4. Standardized estimates of relative risk (SERR) for
progression to microalbuminuria microalbuminuria, adjusting for duration, HbA1c,
and AER at baseline
SERR 95% CI P value
Progression to microalbuminuria
HbA1c 1.57 1.26, 1.97 0.0001
Albumin excretion rate 1.45 1.13, 1.87 0.004 Yes No
N  143 N  972 P valueFasting triglyceride 1.31 1.05, 1.65 0.02
WHR 1.27 1.02, 1.58 0.03
Systolic BP mm Hg 12317 11817 0.0005
WHR is waist to hip ratio. Diastolic BP mm Hg 7512 7312 0.02
a SERR was calculated using logistic regression, where all risk factors listed HbA1c % 9.11.6 8.31.3 0.0001
above were included in the model (N  751). Last 2 years HbA1c % 8.81.7 8.12.0 0.0001
Cholesterol mmol/L 5.31.2 5.21.1 0.2
Fasting triglyceridea
mmol/L 1.11 (1.01, 1.22) 0.96 (0.93, 1.00) 0.005
HDL mmol/L 1.640.40 1.660.44 0.5ressors, there was little change in nonprogressors (0.5 
LDL mmol/L 3.31.0 3.11.0 0.006
16.9, P  0.0004). Similarly, using the HbA1c conversion
Data are mean SD. Abbreviations are: AER, albumin excretion rate; HDL,
to the DCCT values at both baseline and follow-up, the high-density lipoprotein; LDL, low-density lipoprotein.
a Geometric mean (95% CI)change in HbA1c was 2.1  13.9% in progressors and
–0.7  12.6% in nonprogressors (P  0.02).
DISCUSSION value is 6, this latter difference can be shown with the
numbers we have with P  0.016 and a power of 76%Over seven years, the incidence of microalbuminuria
(these power calculations have been corrected to takein the EURODIAB cohort of type 1 patients was 12.6%
into consideration multiple significance testing that has(1.8 per 100 person-years). To our knowledge this is
to be performed in the process of the segmented regres-the largest study examining microalbuminuria incidence.
sion analysis) [17, 25]. Thus, should a threshold exist, weComparisons between studies are difficult, as potential
had sufficient power to detect it. While a single baselinedeterminants of microalbuminuria, such as age, duration,
measurement of HBA1c may not represent the total gly-blood pressure, and glycated hemoglobin inclusion crite-
cemic control that an individual is exposed to, as controlria may differ, but our estimate falls within the range of 1
“tracks” within individuals, it is likely that the relativeto 3% per annum anticipated by previous studies [20–22],
ranking of each individual would not change had weand is close to the incidence of 14.5% over seven years
taken several baseline measurements. Furthermore, wefound by the Microalbuminuria Collaborative Study
cannot be sure that glycemic control was captured at aGroup [23]. The incidence in our study is probably under-
time when the initiation of microalbuminuria would takeestimated, as those who were lost to follow-up had worse
place, but again, our argument regarding tracking stillglycemic control at baseline. However, even taking this
applies. These limitations would apply to the previousinto account, our estimates are much lower than those
analyses of a threshold effect.derived from the U.S. Epidemiology of Diabetes Compli-
Apart from well-known risk factors such as HbA1c andcations Study (EDC), which had an incidence of micro-
AER at baseline [5, 24, 26, 27], independent associationsalbuminuria over two years of 9.4% [24]. The most likely
were also observed with fasting triglyceride and WHR.explanation for this discrepancy is the poorer glycemic
Data from previous cross-sectional studies show that lip-control in the U.S. cohort compared to EURODIAB at
ids are abnormal in patients with microalbuminuriabaseline [9].
[28–31] and, more importantly in terms of assessing cau-One of the main factors accounting for risk of progres-
sality, that apolipoprotein B levels [32] and LDL choles-sion to microalbuminuria was glycemic control. Others
terol [24] are elevated in those at risk of subsequenthave vigorously argued for a glycemic threshold for risk
microalbuminuria. Interestingly, while many of the lipidof microalbuminuria [6]. This finding is not supported
parameters measured here are highly correlated, it is strik-by larger cross-sectional studies, and the DCCT provides
ing that only triglyceride remains significant, despite beingno support for this contention [7, 8]. Here, in the largest
less precisely measured than total and HDL cholesterol.observational follow-up study, we also demonstrate that
To our knowledge, no previous study has explored thethere is no glycemic threshold for risk of microalbumin-
predictive role of central obesity in microalbuminuria oruria, and efforts to reduce HbA1c should therefore be
examined whether these factors are independent of distur-continued at all levels. Clearly, there may be limitations
bances in blood glucose. In EURODIAB, both triglycer-to our threshold analysis. A post hoc power calculation
ide and WHR were independent of glycated hemoglobinindicates that if the difference in the odds ratio for pro-
and AER at baseline. Furthermore, when the strengthgression to microalbuminuria from the first to the median
of key risk factors was compared by using standardizedvalue of HbA1c (median HbA1c 6%) is 1 and the differ-
ence in the odds ratio from the median to the last HbA1c estimates of risk, we observed that both fasting triglycer-
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ide and WHR were nearly as strong as baseline AER nonprogressors, a tentative interpretation is that the in-
crease in AER either precedes or is concomitant within predicting microalbuminuria.
Both of these factors are features of the insulin-resis- that of blood pressure. This has been a controversial
topic, with some arguing in favor of this temporal se-tance syndrome [33], and there is evidence that type 1
diabetes is associated with insulin resistance [34]. This quence [20, 24, 27] and some against it [23, 52]. All
centers were trained and tested to the same protocolis predictive of vascular disease [35], is more pronounced
in those with microalbuminuria [36], and is also evident for the study so that our measurement of resting blood
pressure was well standardized. However, resting bloodin family members of patients with type 1 diabetes [37].
Insulin resistance and at least overall obesity is associ- pressure cannot capture the whole picture of blood pres-
sure occurring over a 24-hour period, and considerableated with microalbuminuria in some [38] but not all stud-
ies in the general population [39], and in type 1 diabetes, differences in 24-hour profiles have been observed, even
in normoalbuminuric patients [53]. Interestingly, severalinsulin resistance predates the onset of microalbumin-
uria [40]. Although there were no direct measures of normoalbuminuric patients were on antihypertensive
therapy at follow-up (12.6%). Approximately 80% ofinsulin resistance in our study, triglyceride and WHR
are key features of the syndrome, while factors such this therapy could be accounted for by a diagnosis of
hypertension at either baseline or follow-up.as blood pressure are less consistently associated. Our
demonstration of an impact of these factors on AER, There are limitations to this study. Follow-up data
were obtained in 62% of potentially available patients.independent of glycemic control, emphasizes their im-
portance as risk factors and further indicates that the Given the wide European base for this study, this is a
highly respectable follow-up rate for such a cohort study.mechanism of action is not entirely via glycemic control.
The mechanisms by which insulin resistance and micro- Patients who are lost to follow-up tend to have a worse
risk factor profile, and we showed this to be the case foralbuminuria may be linked in type 1 diabetes are not clear.
There are two categories of explanation: either insulin glycated hemoglobin and AER. Therefore, the risk of
microalbuminuria may be underestimated, but it is un-resistance has a direct pathological effect on the kidney
to cause microalbuminuria [41–44], or the two factors likely that our conclusions on risk factor relationships,
which are the main findings of this analysis, would differ,cluster together and are in turn caused by another factor.
An interesting candidate for this latter role is endothelial as it would be hard to hypothesize a situation where, for
example, WHR was positively related to risk of progres-dysfunction, which is related to reduced insulin action
on the one hand and enhanced capillary leakage of albu- sion in responders and negatively related in nonrespond-
ers. The strengths of this analysis are that all measure-min on the other [45]. To support the latter, there is
evidence that endothelium-dependent vasodilation is im- ments were performed using a standard protocol, which
investigators were well acquainted with from the base-paired in people with type 1 diabetes, and again more
marked in those with microalbuminuria [46]. This has line investigations until the end of the study. Further-
more, while the number of observers for some of thealso been shown in insulin resistance [47]. The presence
of other complications at baseline, such as peripheral measures, in particular blood pressure and WHR, may
have introduced precision variability, this would be non-neuropathy and retinopathy, also predicted the incidence
of microalbuminuria at follow-up. Again, this supports differential. In other words, it is unlikely that investiga-
tors consistently underestimated WHR in those whothe notion of a generalized state of endothelial dysfunc-
tion, which enhances the risk of all complications [48]. were persistently normoalbuminuric and overestimated
in those with incident microalbuminuria. Given this vari-However, there was no difference at baseline in vWF,
which is commonly used as a marker of endothelial dys- ability, it is even more surprising that such a strong asso-
ciation is noted between WHR and microalbuminuria,function, in those who progressed to microalbuminuria
compared with those who remained normoalbuminuric. and with a more precise measure this association may
be even stronger. A similar argument applies to the urineThis is in contrast to some [49] but not all [50] previous
findings. It is difficult to account for this discrepancy, collections. Investigators were trained to a standard pro-
tocol, and any inaccuracies in collection would be nondif-particularly as we have shown a relationship between
vWF and microalbuminuria cross-sectionally [51]. It may ferential, that is, not systematically biased by risk factor
status or outcome. The same laboratory was used forbe that changes in endothelial dysfunction before devel-
opment of microalbuminuria are too subtle to be de- measurement of urinary albumin at both baseline and
follow-up; the fact that we had one urine collection attected by vWF levels at this early stage.
Interestingly, blood pressure and smoking did not ap- baseline and two at follow-up should not seriously affect
the assessment of risk factor relationships.pear to be risk factors, even in the univariate models.
However, when follow-up data were compared, resting We conclude that the risk of microalbuminuria re-
mains high in type 1 diabetes and that glycemic controlblood pressure was higher in incident cases. As AER at
baseline was significantly greater in progressors versus is one of the strongest predictors of this risk, with no
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Italy); N. Papazoglou and G. Manes (General Hospital of Thessaloniki,evidence of a threshold effect, supporting efforts to keep
Greece); M. Muggeo and M. Iagulli (Cattedra di Malatties del Metabo-
HbA1c levels as low as possible. Microalbuminuria is lismo, Verona, Italy); K. Irsigler and H. Abrahamian (Hospital Vienna
Lainz, Vienna, Austria); S. Walford, E.V. Wardle, J. Sinclair, and S.strongly determined by markers of the insulin resistance
Hughes (New Cross Hospital, Wolverhampton, UK); G. Roglic, Z.syndrome, particularly triglyceride and WHR. The close
Metelko, and Z. Resman (Vuk Vrhovac Institute for Diabetes, Zagreb,
relationship between lipids and microalbuminuria has Croatia).
The Steering Committee Members: J.H. Fuller (London), B. Kara-important implications for treatment. A study in type 2
manos, Chairman (Athens), A.-K. Sjolie (Aarhus), N. Chaturvedi (Lon-diabetes indicated that statin therapy reduced albumin-
don), M. Toeller (Dusseldorf), G. Pozza, co-chairman (Milan), B. Fer-
uria by 25% [54], although this could not be replicated riss (Cork), M. Porta (Turin), R. Rottiers (Gent), and G. Michel
(Luxembourg).in type 1 patients, possibly because of an inadequate
Co-ordinating Center: J.H. Fuller, N. Chaturvedi, J. Holloway, D.sample size [55]. Other indications that both insulin resis-
Webb, and L. Asbury (University College London).
tance and microalbuminuria share a common antecedent The Central Laboratories: G.-C. Viberti, R. Swaminathan, P. Lumb,
A. Collins, and S. Sankaralingham (Guy’s and St. Thomas’ Hospital,are tantalizing and require further investigation.
London, UK).
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